Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PROTHENA CORP PUBLIC LTD CO files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.06
27.5
0.96
0.81
0.85
201
53.9
91.4
135
9.68
Research and development
120
135
101
50.8
74.9
82.3
136
221
223
135
General and administrative
41.1
48.2
42.5
35.7
38.7
46.3
49.9
61.8
67.2
59.4
Operating expenses
161
183
160
86.5
114
129
185
282
290
224
Operating income
-160
-155
-159
-85.7
-113
72
-132
-191
-155
-215
Other non-operating income
0.57
-2.35
2.74
8.4
1.31
-0.05
5.95
30.6
25.6
13.8
Pre-tax income
-159
-158
-156
-77.3
-111
71.9
-126
-160
-129
-201
Income tax
1.14
-4.37
-0.47
0.38
-0.28
4.95
-8.66
-13.5
-6.62
43.3
Net income
-160
-153
-156
-77.7
-111
67
-117
-147
-122
-244
EBITDA
-157
-152
-156
-84.1
-111
73.1
-131
-190
-154
-214
EPS, basic
-4.66
-4.07
-3.93
-1.95
-2.78
1.51
-2.47
-2.76
-2.27
-4.53
EPS, diluted
-4.66
-4.07
-3.93
-1.95
-2.78
1.38
-2.47
-2.76
-2.27
-4.53
Shares, basic (weighted)
34.4
37.7
39.6
39.9
39.9
44.2
47.4
53.2
53.8
53.8
Shares, diluted (weighted)
34.4
37.7
39.6
39.9
39.9
48.5
47.4
53.2
53.8
53.8
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
387
418
428
376
295
579
710
619
471
308
Receivables
0.18
0.24
0
0.07
0.02
0
0
5.16
0
Other current assets
4.26
8.47
3.73
2.58
2.54
5.72
8.69
13.9
14
7.66
Total current assets
391
426
431
378
299
585
719
639
485
315
Property, plant and equipment
56.5
55
52.8
3.87
2.55
2.01
1.73
3.84
3.08
2.14
Lease right-of-use assets
0
23.3
17.8
12.1
6.28
12.2
10.7
8.13
Other non-current assets
2.19
2.84
0.81
1.09
0.33
2
10.5
6.35
3.81
0.48
Total assets
460
496
499
419
333
609
758
696
547
327
Accounts payable
13.1
13.6
1.47
1.24
4.12
3.69
9.27
25.4
7.77
5.88
Accrued liabilities
6.63
7.34
4.51
4.82
5.93
8.64
11.1
13.2
14.5
11.4
Deferred revenue
0
7.66
11.4
0
8.85
2.66
Total current liabilities
41.1
37.4
14.9
17.7
25.8
33.5
50.1
56.9
48.5
40.8
Lease liabilities
0
17.8
12.3
6.39
0
10.7
8.23
5.49
Other non-current liabilities
0
0
0.55
0.55
0.55
0.55
0.55
0
Total liabilities
94.6
89.1
176
146
149
143
136
135
60.2
46.3
Paid-in capital
654
849
921
944
967
1,182
1,455
1,541
1,589
1,626
Retained earnings
-289
-442
-598
-672
-783
-716
-833
-980
-1,102
-1,346
Shareholders' equity
365
407
323
273
184
466
622
561
487
280
Total equity
365
407
323
273
184
466
622
561
487
280
Total liabilities and equity
460
496
499
419
333
609
758
696
547
327
Shares outstanding
34.8
38.5
39.9
39.9
39.9
46.7
52.1
53.7
53.8
53.8
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-160
-153
-156
-77.7
-111
67
-117
-147
-122
-244
Depreciation and amortization
2.43
3.07
3.22
1.56
1.51
1.12
0.74
0.93
0.89
0.9
Stock-based compensation
24.9
26.8
27
23.6
22
24.7
31.3
40.9
46
37.6
Deferred income tax
-3.32
-2.2
-1.59
-1.25
-1.69
4.57
-11.1
-15.7
-9.35
43.2
Change in receivables
0.33
-0.06
0.24
0
0.05
0.02
0
-5.16
5.16
0
Change in payables
15.2
0.15
-25.6
-0.08
7.73
-0.49
11.9
22.9
-18.3
-15.8
Cash from operations
-116
-131
-28.3
-53
-80.4
92.6
-109
-134
-150
-164
Cash from investing
-16.6
-3.52
-1.73
-0.55
-0.2
-0.58
-0.46
-2.77
-0.3
-0.14
Stock issued
129
150
0
0
0
78
17.8
21.5
1.91
0
Cash from financing
153
165
40
0.23
0.22
190
241
45.1
1.55
-0.14
Net change in cash
20.4
30.7
10
-53.3
-80.3
282
132
-91.6
-149
-164
Income taxes paid
0.58
0.29
-1
1.58
1.37
0.58
2.66
1.55
3.17
0.93
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.29 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-101.8%
Operating income / revenue.
EBITDA margin
-100.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-81.3%
Pre-tax income / revenue.
Net margin
-80.7%
Net income / revenue.
Operating cash flow margin
-110.1%
Cash from operations / revenue.
Return on equity (ROE)
-15.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-14.5%
Net income / average total assets.
R&D / revenue
119.1%
Research and development expense / revenue.
Stock-based pay / revenue
53.3%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
1.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-92.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-43.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
62.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-42.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-23.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
8.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-40.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-24.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-0.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
4.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
6.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
25.0x
Current assets / current liabilities.
Quick ratio
24.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
24.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.05
Revenue / diluted weighted shares.
Operating cash flow per share
-$1.15
Cash from operations / diluted weighted shares.
Book value per share
$5.54
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
7.80x
Market cap / revenue.
P/B
1.48x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.48x
Market cap / tangible book value, when positive.
EV/Sales
2.52x
Enterprise value / revenue.
Earnings yield
-10.3%
Net income / market cap (the inverse of P/E).
What was PROTHENA CORP PUBLIC LTD CO's revenue in fiscal 2025?
PROTHENA CORP PUBLIC LTD CO reported revenue of $9.7M for fiscal 2025, 92.8% lower than the year before.
Was PROTHENA CORP PUBLIC LTD CO profitable in fiscal 2025?
No. It reported a net loss of $244.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.